- Home
- RLX vs ADRX Comparison
RLX vs ADRX Comparison
Compare RLX & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLX | ADRX |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | RLX | ADRX |
|---|---|---|
| Price | $1.62 | $13.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $2.78 | ★ $34.25 |
| AVG Volume (30 Days) | ★ 1.4M | 372.1K |
| Earning Date | 11-17-2026 | 11-19-2026 |
| Dividend Yield | ★ 6.71% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.88 | $72.35 |
| Revenue Next Year | $23.93 | $570.74 |
| P/E Ratio | $28.09 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $14.85 |
| 52 Week High | $2.60 | $19.57 |
Technical Indicators
Market Signals| Indicator | RLX | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 27.39 |
| Support Level | $1.58 | N/A |
| Resistance Level | $1.75 | $19.01 |
| Average True Range (ATR) | 0.05 | 1.32 |
| MACD | 0.00 | -0.25 |
| Stochastic Oscillator | 35.50 | 2.72 |
Price Performance
Historical ComparisonAbout RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.